An Introduction to Molecular Testing
An Introduction to Molecular Testing
Listen to PRECISION ONCOLOGY CONNECT experts in conversation
Listen to PRECISION ONCOLOGY CONNECT experts in conversation
Dr Tracy L Stockley, Prof. David Hong
In this podcast, Dr Tracy Stockley and Prof. David Hong come together to provide an introduction to molecular testing.
Listen as they discuss:
- Why identifying genetic alterations is so important
- How targeted therapies impact outcomes
- When to use molecular profiling
- Which methods of genetic testing to choose
Dr Tracy L Stockley
Pathologist and Geneticist
University Health Network, Toronto
Canada
Dr Stockley is the Head of the Department of Clinical Laboratory Genetics at the University Health Network in Toronto. The Department is the largest molecular pathology laboratory service in Canada and consists of two labs, the translational Advanced Molecular Diagnostics Laboratory at the Princess Margaret Cancer Center, and the clinical Genome Diagnostics Laboratory at Toronto General Hospital. Dr Stockley’s role at UHN includes oversight of genetic testing for oncology including companion diagnostics, genomic test development for clinical laboratory use, and applications of next-generation sequencing to clinical care. Dr Stockley has an interest in quality improvement related to high-complexity laboratory testing, and has participated in standard development for molecular diagnostics with multiple national and international organizations including Health Canada, Clinical Laboratory Standards Institute (CLSI), European Molecular Quality Network and the International Organization for Standardization (ISO). Dr Stockley is an Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, and the current President of the Canadian College of Medical Geneticists.
Dr Tracy L Stockley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Astellas, Bayer, Bristol Myers Squibb and Janssen.
Prof. David Hong
Medical Oncologist
MD Anderson Cancer Center, Houston
United States (US)
Dr David S. Hong is a Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program), Clinical Medical Director of the Clinical Translational Research Center (CTRC), and Associate Vice President of Clinical Research at The University of Texas MD Anderson Cancer Center.
Dr Hong was instrumental in forming one of the largest and most innovative Phase 1 clinical trial units in the world, with over 1300 patients enrolled in clinical trials in FY2021 and over 400 active ongoing clinical trials.
Dr Hong has been the Principal Investigator of over 120 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. He has published over 374 publications in Peer-reviewed Journals such as NEJM, Lancet Oncology, JCO and Nature.
He has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib, larotrectinib, tesotumab vendotin, and sotorasib the first drug to target KRAS that have led to FDA approval.
He has also helped found 2 companies OncoResponse and Telperian.
He is an expert on c-Met, NTRK, KRAS, and adoptive cellular therapy in solid tumors and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial. He been awarded the ASCO Young Investigator Award, the Jesse Jones award, Best Boss award at MD Anderson, Irwin Krakoff Award for Clinical Research, and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson.
Prof. David Hong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astra-Zeneca, Bayer, Bristol- Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Endeavor, Erasca, F. Hoffmann- LaRoche, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, TCR2, Teckro, Turning Point Therapeutics and VM Oncology.
An introduction to molecular testing
Podcast |
24 min
|
Jul 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Clinical takeaways
-
Identification of actionable genetic alterations and treatment with an associated targeted therapy can achieve significant outcomes for cancer patients
-
Molecular profiling should be routine both at the point of diagnosis and at progression for cancer patients wherever possible
-
Tumour biopsy is the gold standard for genetic testing, but ctDNA can be an alternative for tumours that are difficult to biopsy and also is associated with a faster turnaround time
This educational programme is supported by an Independent Medical Education Grant from Bayer.
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.
Other programmes of interest
Other programmes developed by Prof. David Hong
Prof. David Hong
Medical Oncologist
MD Anderson Cancer Center, Houston
United States (US)